CT-305: Optimizing Post-Chimeric Antigen Receptor (CAR) T-Cell Monitoring: Evidence Across Lisocabtagene Maraleucel (liso-cel) Pivotal Clinical Trials and Real-World Experience
Manali Kamdar(University of Colorado Cancer Center), Matthew A. Lunning(University of Nebraska Medical Center), Abu‐Sayeef Mirza(University of South Florida), Alberto Vasconcelos(Bristol-Myers Squibb (Switzerland)), Sairah Ahmed(The University of Texas MD Anderson Cancer Center), David Bernasconi(Bristol-Myers Squibb (United States)), Alessandro Crotta(European Organisation for Rare Diseases), Iris Isufi(Yale University), Matthew J. Frigault(Harvard University), Bradley D. Hunter(Intermountain Healthcare), David B. Miklos(Stanford University), Miguel‐Angel Perales(Memorial Sloan Kettering Cancer Center), Marcelo C. Pasquini(Cleveland Clinic), Eric Bleickardt(Unknown), Jennifer L. Crombie(Dana-Farber Cancer Institute), Nausheen Ahmed(Health Care Foundation of Greater Kansas City), Debasmita Roy(Bristol-Myers Squibb (United States)), Mazyar Shadman(University of Washington), Jeremy S. Abramson(Massachusetts General Hospital)
Cited by 1
Related Papers
Lenalidomide after Stem-Cell Transplantation for Multiple Myeloma
|New England Journal of Medicine|2012|1.1k
The effects of intestinal tract bacterial diversity on mortality following allogeneic hematopoietic stem cell transplantation
|Blood|2014|880
Standard-of-Care Axicabtagene Ciloleucel for Relapsed or Refractory Large B-Cell Lymphoma: Results From the US Lymphoma CAR T Consortium
|Journal of Clinical Oncology|2020|782
Intestinal Blautia Is Associated with Reduced Death from Graft-versus-Host Disease
|Biology of Blood and Marrow Transplantation|2015|762
Microbiota as Predictor of Mortality in Allogeneic Hematopoietic-Cell Transplantation
|New England Journal of Medicine|2020|739